

ASX Release 29 April 2025

**ASX code: PIQ** 

# Notice under Section 708A(5)(e) of the Corporations Act 2001

This notice is given by Proteomics International Laboratories Ltd ACN 169 979 971 (**PIQ** or **Company**) under section 708A(5)(e) of the Corporations Act 2001 (Cth) (**Corporations Act**).

## Details of the securities issued

Class / description	Ordinary Shares (Shares)
ASX code	PIQ
Date of issue	29 April 2025
Number issued	10,810,811

The Company gives notice pursuant to section 708A(5)(e) of the Corporations Act that:

- 1. the Company issued the Shares without disclosure under Part 6D.2 of the Corporations Act;
- 2. as at the date of this notice, the Company has complied with:
  - (i) the provisions of Chapter 2M of the Corporations Act as they apply to the Company; and
  - (ii) sections 674 and 674A of the Corporations Act; and
- 3. as at the date of this notice there is no information to be disclosed which is 'excluded information' (as defined in sections 708A(7) and 708A(8) of the Corporations Act) which is required to be disclosed by the Company.

Authorised by the Chairman and the Managing Director of PIQ on behalf of the Board.

#### **ENDS**

### About Proteomics International Laboratories (PILL) (www.proteomicsinternational.com)

Proteomics International (Perth, Western Australia) is a wholly owned subsidiary and trading name of PILL (ASX: PIQ), a medical technology company at the forefront of precision diagnostics and bio-analytical services. The Company specialises in the area of proteomics – the industrial scale study of the structure and function of proteins. Proteomics International's mission is to improve the quality of lives by the creation and application of innovative tools that enable the improved treatment of disease.

## For further information please contact:

Dr Richard Lipscombe

Managing Director

Proteomics International Laboratories Ltd

T: +61 8 9389 1992

Dirk van Dissel
Investor Relations
Candour Advisory
T: +61 408 326 367